Lataa...
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
BACKGROUND: Triple negative breast cancer (TNBC) is an incurable disease where novel therapeutic strategies are needed. Proteolysis targeting chimeric (PROTAC) are novel compounds that promote protein degradation by binding to an ubiquitin ligase. In this work, we explored the antitumoral activity o...
Tallennettuna:
| Julkaisussa: | J Exp Clin Cancer Res |
|---|---|
| Päätekijät: | , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6717344/ https://ncbi.nlm.nih.gov/pubmed/31470872 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1387-5 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|